Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276

Watchlist Manager
Jiangsu Hengrui Pharmaceuticals Co Ltd Logo
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Watchlist
Price: 52.9 CNY 3.26% Market Closed
Market Cap: 337.4B CNY

Jiangsu Hengrui Pharmaceuticals Co Ltd
Other

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jiangsu Hengrui Pharmaceuticals Co Ltd
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other
-ÂĄ918.7m
CAGR 3-Years
-28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other
-ÂĄ3.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other
-ÂĄ56.1m
CAGR 3-Years
-20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other
-ÂĄ98.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhejiang Nhu Co Ltd
SZSE:002001
Other
ÂĄ80.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other
-ÂĄ72.7m
CAGR 3-Years
N/A
CAGR 5-Years
-22%
CAGR 10-Years
N/A

Jiangsu Hengrui Pharmaceuticals Co Ltd
Glance View

Economic Moat
Narrow
Market Cap
337.4B CNY
Industry
Pharmaceuticals

Nestled in the throbbing economic heart of China's Jiangsu province, Jiangsu Hengrui Pharmaceuticals Co Ltd has carved a niche as a formidable player in the global pharmaceutical landscape. Established in 1970, this company has evolved from its humble beginnings into a powerhouse known for its relentless focus on research and development, a keystone in its operational strategy. Hengrui has built a diverse portfolio of products, primarily focusing on oncological, cardiovascular, and anti-diabetic therapeutics. The company leverages its state-of-the-art R&D facilities and a team of top-tier scientists to innovate and advance new treatment solutions, which are then patented to ensure exclusivity and competitive market positioning. In addition to its robust R&D-driven pipeline, Hengrui thrives through strategic collaborations and international partnerships that enhance its market reach and deepen its competitive moat. Revenue generation springs from a dual-engine model: sales of proprietary drugs and a burgeoning generic drug segment that ensures steady cash flow. Furthermore, Hengrui's ability to navigate the intricate regulatory landscapes of different countries enables it to market its innovative therapies globally, thus broadening its revenue streams. With an eye toward sustainable growth, the company continually reinvests a significant portion of its profits back into R&D, sustaining its cycle of innovation and market leadership, while also playing a vital role in meeting global healthcare needs.

Intrinsic Value
38.43 CNY
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Other?
Other
-918.7m CNY

Based on the financial report for Mar 31, 2025, Jiangsu Hengrui Pharmaceuticals Co Ltd's Other amounts to -918.7m CNY.

What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Other growth rate?
Other CAGR 3Y
-28%

Over the last year, the Other growth was -38%. The average annual Other growth rates for Jiangsu Hengrui Pharmaceuticals Co Ltd have been -28% over the past three years .

Back to Top